We produce and develop drugs and vaccines that big pharmaceutical companies are not interested in due to their lack of a commercial market so that these products can be stockpiled and be made available in an emergency situation.
Established in 2018, Global Urgent and Advanced Research and Development (GUARD) executes pre-clinical and clinical development strategies on prophylactic and therapeutic products for neglected emerging infectious diseases.
A main objective is to accumulate clinical data packages within rigorous regulatory processes to support further clinical progression during outbreaks and contribute to global stockpiles and security.
GuardRX envisions becoming a global resource for the clinical development and stockpiling of these products by:
- Acquiring licenses for products in advanced stages of pre-clinical development that would otherwise not enter the clinic;
- Establishing connections with funding agencies, CMOs, CROs, and global stockpile institutions; and,
- Delivering products with initial clinical data packages developed with rationalized resource investment in order to optimize the response to emergencies of public health concern.